

**ERN ITHACA Webinar #8** "In-depth" Fetal surgery for omen dysraphisms

Tuesday oct 19 - 2023

from 5pm to 6.30 pm French time

### Chaired Pr Jean-Marie Jouannic Co Chair – ITAHCA -WG SBoD

Department of Fetal Medicine, Trousseau Hospital, APHP. Sorbonne University Medicine, Paris, France





### Welcome – Technical points

- We are pleased to be numerous 58
- Webinar is being recorded
- Thank you for
  - Turn off your microphone and disconnect your camera
  - Raise your hand at the time of the questions and discussions
  - We will answer the questions sent in the registration form
  - A satisfaction survey will be sent to you
- Webinars # will be available on ITHACA's Website

https://ern-ithaca.eu/documentation/educational-resources/

Anne Hugon Project Manager ERN ITHACA - anne.hugon@aphp.fr





### Survey registration feed back

- 58 Registrations
- 31 ITHACA's members
- 27 others
- I Question : How do you see fetal surgery evolving over the next 10 years?







# WP T&E - Welcome and Introduction

#### Pr Jean-Marie Jouannic

Department of Foetal Medicine, ORIGYNE Medical and University Department, Trousseau Hospital, APHP. Sorbonne University Medicine, Paris, France

• The perinatal management of myelomeningocele has been modified following the demonstration of the benefits of fetal surgery, which reduces postnatal handicaps. The SBoD group, which is a trans-ERN group involving colleagues from ERN ITHACA and eUROGEN, is dedicated to the lifelong management of patients with SB or other dysraphisms. In this Webinar, recent aspects of fetal surgery for myelomeningocele will be presented by European specialists from the WG SBoD group.



### Agenda

- Welcome and Introduction
  - Pr Jean-Marie Jouannic, Trousseau Hospital, APHP. Sorbonne University Medicine, Paris, France
- Fetoscopic repair: results from the Val d'Hebron center
  - Pr Elena Carreras, Val d'Hebron Hospital, Barcelona
- Open surgery: technical improvements to limit obstetrical complications
  - Pr Jan Deprest, Leuven, Belgium
- Are intermediate forms of dysraphism eligible for fetal surgery?
  - Pr Jean-Marie Jouannic, Dr Timothée de Saint Denis, Trousseau Hospital, Paris, France
- A role for stem cell therapy to improve the motor prognosis?
  - Dr Lucie Guilbaud, Trousseau Hospital, Paris, France
- Discussion time 20'
- Conclusion with speakers and moderator

ERN ITHACA Webinar #8 "In-depth" Fetal surgery for open dysraphisms

Fetoscopic repair: results from the Vall d'Hebron center

Elena Carreras, Nerea Maiz, Silvia Arévalo, Manuel López, Carles Giné Hospital Universitari Vall d'Hebron de Barcelona





### Fetoscopy for Neural Tube Defects

#### Approach



### **Surgical technique**



✓ Obstetrical Outcomes

✓ NTD and baby outcomes Reference Networks



### Fetoscopy for Neural Tube Defects

### Approach

- ✓ Completely Percutaneous
- ✓ Hybrid exteriorized uterus
  - ✓ Two ports
  - ✓ Three ports

- ✓ Percutaneous with mini
  - incisions to place the ports

#### **Surgical technique**









### Approach

#### **Exteriorized uterus**

#### Risvadtageage

- ✓ Mataremblamarotomye → post urgical pain control
- ✓ Sotspeetfcthe membranes → larger time to delivery
- ✓ Shorter instruments more precision
- ✓ Small cannulas (2-3 mm)
- ✓ Less CO2 pressure (6-8 mmHg versus 12-15 or more)
- ✓ Better mobilization of the fetus
- ✓ Easier fetal monitoring







Ultrasound Obstet Gynecol 2019; 53: 855-863 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.20308

#### Proceedings of the First Annual Meeting of the International Fetoscopic Myelomeningocele Repair Consortium

M. SANZ CORTES<sup>1</sup>, D. A. LAPA<sup>2</sup>, G. L. ACACIO<sup>3</sup>, M. BELFORT<sup>1,4</sup>, E. CARRERAS<sup>5</sup>, N. MAIZ<sup>5</sup>, J. L. PEIRO<sup>6</sup>, F. Y. LIM<sup>6</sup>, J. MILLER<sup>7</sup>, A. BASCHAT<sup>7</sup>, G. SEPULVEDA<sup>8</sup>, I. DAVILA<sup>8</sup>, Y. GIELCHINSKY<sup>9,10</sup>, M. BENIFLA<sup>11</sup>, J. STIRNEMANN<sup>12</sup>, Y. VILLE<sup>12</sup>, M. YAMAMOTO<sup>13</sup>, H. FIGUEROA<sup>13</sup>, L. SIMPSON<sup>14</sup> and K. H. NICOLAIDES<sup>15</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA; <sup>2</sup>Fetal Therapy Program, Hospital Israelita Albert Einstein, São Paulo, Brazil; <sup>3</sup>Department of Obstetrics, Universidade de Taubate, São Paulo, Brazil; <sup>4</sup>Department of Neurosurgery, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA; <sup>5</sup>Department of Obstetrics and Gynecology, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; <sup>6</sup>Department of Pediatric Surgery, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, OH, USA; <sup>7</sup>Department of Gynecology and Obstetrics, Johns Hopkins Center for Fetal Therapy, Baltimore, MD, USA; <sup>8</sup>Medicine Perinatal Alta Especialidad, Hospital Christus Muguerza Alta Especialidad, Monterrey, NL, Mexico; <sup>9</sup>Department of Obstetrics & Gynecology, Hadasab-Hebrew University Medical Center, Jerusalem, Israel; <sup>10</sup>Department of Obstetrics & Gynecology, Rabin Medical Center, Petach Tikva, Israel; <sup>11</sup>Feidatric Neurosurgery Unit, Rambam Health Care Campus, Haifa, Israel; <sup>12</sup>Department of Obstetrics and Gynecology, Necker-Enfants Malades Hospital, Paris, France; <sup>13</sup>Universidad Los Andes, Santiago de Chile, Chile; <sup>14</sup>Department of Obstetrics and Gynecology, Columbia University Medical Center, Neur York Presbyterian Hospital, New York City, NY, USA; <sup>15</sup>Fetal Medicine Foundation, London, UK



#### OBSTETRICS

#### Experience of 300 cases of prenatal fetoscopic open spina bifida repair: report of the International Fetoscopic Neural Tube Defect Repair Consortium



.atl

Magdalena Sanz Cortes, MD; Ramen H. Chmait, MD; Denise A. Lapa, MD; Michael A. Belfort, MD; Elena Carreras, MD; Jena L. Miller, MD; Robert Brawura Biskupski Samaha, MD; Gerardo Sepulveda Gonzalez, MD; Yuval Gielchinsky, MD; Masami Yamamoto, MD; Nicola Persico, MD; Marta Santorum, MD; Lucas Otaño, MD; Ermos Nicolaou, MD; Yoav Yinon, MD; Fernanda Faig-Leite, MD; Reynaldo Brandt, MD; William Whitehead, MD; Nerea Maiz, MD; Ahmet Baschat, MD; Przemyslaw Kosinski, MD; Adriana Nieto-Sanjuanero, MD; Jason Chu, MD; Amir Kershenovich, MD; Kypros H. Nicolaides, MD







- Exbenence of Pan cases of bieners istoscobic obsitisbute surger cabet.
- Report of the International Fetoscopic Neural Tube Defect Repair Consortium
- Report of Vall d'Hebron University Hospital

Variable	Consortium N=300	Post-MOMS N=100	P value	Vall d'Hebron N=46
Gestational age at surgery	25.9 (22.7-31.6)	23.3 (20.2- 25.6)	-	24.7 (23.9-25.4)
Placental abruption	25/280 (8.9%)	2/96 (2.1 %)	0.022	0
Chorioamniotic membrane separation	72/190 (37.9%)	22/96 (22.9%)	0.012	11/40 (27.5%)
Oligohydramnios	53/267 (19.9%)	6/96 (6.3%)	0.001	1/40 (2.5%)
Preterm prelabor rupture of membranes	153/280 (54.6%)	31/96 (32.3%)	0.0002	20/40 (50%)



### Vall d'Hebron technique

### Approach:

• Hybrid: exteriorized uterus

### **Surgical Technique: always 3-port**

- Plan A: Two Layer closure
- Plan B: Myofascial patch and skin closure
- Plan C: Myofascial patch and Skin patch



### Fetoscopy for Neural Tube Defects

### Approach



### **Surgical technique**

- ✓ Cover with a patch (stitched)
- ✓ Patch & Glue
- ✓ Single layer closure
- ✓ Two-layer closure (myofascial and skin)
- ✓ Three-layer closure (duramater, myofascial, skin)
- ✓ Hybrid techniques (myofascial patch and skin, myofascial and patch in skin...)



#### Dissection

- ✓ NOT TOUCH neural tissue
- ✓ Identify neural roots
- ✓ Resect dysplasic tissue as much as possible
- Placode must remain free in the vertebral canal





#### Myofascial

- $\checkmark$  Patch over the placode
- ✓ Direct closure of myofascial layer
- ✓ Defects at least up to 16 mm wide
- ✓ Avoid muscular flaps





#### Myofascial patch

#### $\checkmark$ In cases of:

• Wide defect







#### Myofascial patch

#### $\checkmark$ In cases of:

- Wide defect
- Narrow defect







#### Myofascial patch

#### $\checkmark$ In cases of:

- Wide defect
- Narrow defect
- ✓ Bovine pericardium







#### Skin

✓ Direct closure

- ✓ Release flank incisions
- ✓ Skin flaps
- ✓ Acellular dermal patch





#### Skin

- ✓ Direct closure
- ✓ Release flank incisions
- ✓ Skin flaps
- ✓ Acellular dermal patch





### Case series

#### **75** cases

- ✓ 2011-2013  $\rightarrow$  Open Patch & Glue
- ✓ 2013 2015 → Fetoscopic Patch & Glue
- ✓ 2015 2017  $\rightarrow$  Fetoscopic Skin Closure

- $\rightarrow$  7 cases
- $\rightarrow$  12 cases
- $\rightarrow$  10 cases

✓ 2017 – today  $\rightarrow$  Fetoscopic Two Layer closure

 $\rightarrow$  46 cases

Ultrasound Obstet Gynecol 2018; 52: 452-457 Published online 10 September 2018 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.19104

Fetoscopic two-layer closure of open neural tube defects

C. GINÉ<sup>1,2</sup>, S. ARÉVALO<sup>2,3</sup>, N. MAÍZ<sup>2,3</sup>, C. RODÓ<sup>2,3</sup>, S. MANRIQUE<sup>2,4</sup>, A. POCA<sup>2,5,6</sup>, J. A. MOLINO<sup>1</sup>, E. CARRERAS<sup>3</sup> and M. LÓPEZ<sup>1,2</sup>

<sup>1</sup>Pediatric Surgery Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; <sup>2</sup>Universitat Autònoma de Barcelona, Barcelona, Spain; <sup>3</sup> Maternal-Fetal Medicine Department, Hospital Universitari Vall d'Hebron, Bacelona, Spain; <sup>4</sup> Anesthesiology and Reanimation Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; <sup>§</sup>Pediatric Neurosurgery Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; <sup>6</sup>Neurotraumatology and Neurosurgery Research Unit (UNINN), Barcelona, Spain





#### Case series

### 2017 – today $\rightarrow$ Fetoscopic Two Layer closure $\rightarrow$ 46 cases

- ✓ Three-layer reconstruction (dural suture + myofascial suture + skin suture)  $1/46 \rightarrow 2,2\%$
- ✓ Two-layer reconstruction (dural patch + myofascial suture + skin suture)  $38/46 \rightarrow 82,6\%$
- ✓ Dural patch + myofascial patch + skin suture
  - > Muscular defect too wide  $\rightarrow$  1 patient (22 mm)
  - > Vertebral canal too narrow  $\rightarrow$  4 patients

✓ Dural patch + myofascial patch + dermal patch

Very severe defects



5/46 → 10,9%

 $2/46 \rightarrow 4,3\%$ 



- Experience of 300 cases of prenatal fetoscopic open spina bifida repair:
- Report of the International Fetoscopic Neural Tube Defect Repair Consortium
- Report of Vall d'Hebron University Hospital

Variable	Consortium N=300	Post-MOMS N=100	P value	Vall d'Hebron N=46
Gestational age at delivery (weeks)	34.3 (SD 3.6)	34.3 (22.2-37.49)	-	35.8 (33.6-37.0) 34.9 (SD 3.33)
Cesarean section delivery	192/280 (68.6%)	96/96 (100%)	<0.0001	21/41 (51.2%)

Hydrocephalus treated by shunt or ETV	88/201 (43.8%)	MOMS 31/76 (40.8%)	0,591	13/29 (44.8%)
Motor function compared with upper anatomic level of the lesion				
≥ 2 levels better	98/257 (38.1%)	24/80 (30,0%)	0,231	18/31 (41.9%)
≥ 2 levels worse	12/257 (4.7%)	1/80 (1,3%)	0,315	0







- ✓ Hybrid technique offers critical surgical advantages compared to percutaneous
- ✓ Regardless the approach that may impact the obstetrical outcome, surgical technique must be the key factor in order to compare neurosurgical outcomes
- ✓ Every defect is different and may require a particular surgical solution
- ✓ The surgical team must be prepared to modify its initial technique accordingly

#### Thank you



### TOPIC 2

#### Open surgery: technical improvements to limit obstetrical complications

• Pr Jan Deprest, Leuven, Belgium







Are intermediate forms of dysraphisms eligible for fetal surgery?

> Jean-Marie Jouannic Timothée de Saint Denis









#### Patients referred to Trousseau Fetal center (Jan 2014 – May 2023)



# Limited Dorsal Myeloschisis

Characteristics	Limited dorsal myeloschisis	Myelomeningocele	
Dysraphism	Closed	Open	
Shape of the conus medullaris	Variable (frequently low lying)	Abnormal, Open	
Type of lesion	Saccular *	Saccular	
Peripheral lining	Epithelial	Arachnoid membrane	
Content of the lesion	Fibroneural stalk + cerebrospinal fluid	Nerve roots + neural placode + cerebrospinal fluid	
Cerebral findings	None	Constant (complete Chari II)	













### LDM outcome (N=9)

#### Pregnancy and delivery

- GA at diagnosis: 22+1 weeks (+/- 5d)
- Prenatal anatomical levels: L3-S3
- $\circ$  No cerebral signs
- $\circ~$  AF: normal CGH and AChE negative
- $\circ~$  Delivered at term
  - 4 C section (obstetrical indications)
- Normal birth weight (3140g, range: 2700-4180g)

#### Surgery

- M Zerah and T de Saint Denis
- Median age: 31 d (2-96 d)







### LDM outcome at 36 months

Able to walk	9/9
Autonomous walking	8/9
Walking with orthotics	1/9
Wheelchair	0/9
Urinary catheterization	<b>2/9</b> (S1 level))
Urinary tract infections	0/9
Anticholinergic treatment	1/9

Fully Asymptomatic	5/9
CSF shunt	0/9
Neurodevelopmental retardation	0/9
School without special assistance	9/9
Use of diapers	5/9
Daily transanal enemas	1/9
Laxative treatment	2/9







# LMD: benefit of a prenatal repair?

#### No chiari

Spinal lesions with the increase in the size of the sac?

#### Exception: ruputured of the sac



ULTRASOUDD in Obstetrices & Gynecology Letter to the Editor @ Full Access Ruptured saccular limited dorsal myeloschisis: good indication for fetal repair C. Gine & N. Maiz, S. Arévalo, C. Rodó, M. López, E. Carreras First published: 22 August 2023 | https://doi.org/10.1002/uog.27457















#### Patients referred to Trousseau Fetal center (Jan 2014 – May 2023)



### Myelic Limited Dorsal Malformation: an intermediate form of open dysraphism

Characteristics	Limited dorsal myeloschisis	Myelic limited dorsal malformation	Myelomeningocele
Dysraphism	Closed	Intermediate	Open
Shape of the conus medullaris	Variable (frequently low lying)	Abnormal, attenuated	Abnormal, Open
Type of lesion	Saccular *	Saccular	Saccular
Peripheral lining Epithelial		Epithelial ± arachnoid membrane	Arachnoid membrane
Content of the lesion Fibroneural stalk + cerebrospinal fluid		Variable amount of nerve roots + cerebrospinal fluid	Nerve roots + neural placode + cerebrospinal fluid
Cerebral findings	Cerebral findings None		Constant (complete Chari II)





European Reference Networks

BITHAKA

Spina Bifida and

other Dysraphisms

soin@

ANOMALIES VERTÉBRALES

### MyeLDM: prenatal imaging

#### The Myelic Limited Dorsal Malformation: Prenatal Ultrasonographic Characteristics of an Intermediate Form of Dysraphism

Saskia Vande Perre<sup>a</sup> Lucie Guilbaud<sup>b</sup> Timothée de Saint-Denis<sup>c</sup> Paul Maurice<sup>b</sup> Pauline Lallemant-Dudek<sup>d</sup> Emeline Maisonneuve<sup>b</sup> Ferdinand Dhombres<sup>b</sup> Eléonore Blondiaux<sup>a</sup> Hubert Ducou le Pointe<sup>a</sup> Michel Zerah<sup>c</sup> Jean-Marie Jouannic<sup>b</sup> Catherine Garel<sup>a</sup>

Neural tube malformation	Open	Closed
Major criteria	Chiari II malformation Flattening of frontal bones Neural placode Parallel or everted vertebral laminae Present AChE in the amniotic fluid	No chiari II malformation No frontal bones flattening No neural placode Conus medullaris inside the spinal canal Absent AChE in the amniotic fluid
Minor criteria	Muscular atrophy of the lower limbs Abnormal position of the inferior limbs and feet Nerves roots inside the sac Microcephaly (cranial circumference<3rd percentile) Bilateral ventricular dilatation (>15 mm) Subependymal heterotopia Dysgenesis of the CC (too thick and/or too short)	No muscular atrophy of the lower limbs Normal position of the inferior limbs and feet Slight caudal course of the conus medullaris into the spinal canal



European Reference Networks

ALTHAKA





### MyeLDM outcome (n=8)

#### Pregnancy and delivery (N=8)

- GA at diagnosis: 22 weeks (+/- 6d)
- Prenatal anatomical levels: L2-S3
- Cerebral signs (CII 6/8)
- $\,\circ\,$  AF: normal CGH and AChE positive 6/8
- $\circ~$  Delivered at term
  - 1 C section (obstetrical indications)
- Normal birth weight (3192g, range: 2720-4330g)

#### Surgery

- M Zerah and T de Saint Denis
- Median age: 2 d (0-46 d)



# MyeLDM: outcome at 36 months

Able to walk	8/8
Autonomous walking	6/8
Walking with orthosis	2/8
Wheelchair	0/8
Urinary catheterization	<b>5/8</b> (all sacral levels)
Urinary tract infections	2/8
Anticholinergic treatment	4/8

	Laxative treatment	5/8	
	Retrograde colonic enemas	0/8	
	Use of diapers	8/8	
	School without special assistance	6/8	
	Neurodevelopmental retardation	2/8*	
	CSF shunt	2/8	
	Asymptomatic	2/8	
* Postnatal exome sequencing gene PAK1			

spin@

ANOMALIES VERTÉBRALES ET SPINA BIFIDA European Reference Networks

Spina Bifida and

other Dysraphisms

# Points that need to be balanced

- Open dysraphism
- The spinal cord is streched

- This could be worsened when the sac is closed and increases in volume throughout the pregnancy

- Open dysraphisms are associated with a higher level of spinal cord dysplasia
- MyeLDM may be associated with a better outcome as compared to MMC

### no clear indication

fetal surgery is probably indicated in the more severe cases

benefit of a prenatal detethering of the spinal cord?



ORPHANET classification update (SBoD Trans ERN working group)



#### Types of dysrpahism leading to a functional threatening



Each dysraphism can lead to a neurological impairment by one of these factors or a combination of these four



#### Closure



#### Detethering



Dysraphism surgery consists in an optimisation of a dysplasic spinal cord environment. The dysplasia always remains Goal of multidisciplinary management (including surgery) is to lead to the best global long-term outcome



# Team of Trousseau Hospital for Fetal Surgery

#### Radiology/US/MRI

Catherine Garel Eléonore Bondiaux Toan Nguyen Saskia Vande Perre

#### Neurosurgery

Timothée de Saint Denis M Zerah

#### Anesthesiology

Agnès Rigouzzo Marie-Pierre Bonnet

#### Fetal Medicine and Surgery

Jean-Marie Jouannic Lucie Guilbaud Paul Maurice Loriane Franchinard Ferdinand Dhombres

Pyschologist

Célia du Peuty

#### RPM

Pauline Lallemant Hina Simmonet Rebecca Haddad



Spina Bifida and







(II)  Fetal myelomeningocele surgery: a role for stem cell therapy to improve motor prognosis ?

Lucie Guilbaud, Yoann Athiel, Justine Nasone, Enora Parc, Vincent Mauffré, Pauline Lallemant, Timothée de Saint-Denis, Jean-Marie Jouannic, Jérôme Larghero Department of Fetal Medicine, Trousseau Hospital, APHP. Sorbonne University, Paris, France Stem Cells Biotechnologies, APHP, Inserm U976: Paris, France

ERN ITHACA Webinar #8 "In-depth" - Fetal surgery for open dysraphisms - October 19th , 2023

















### Fetal myelomeningocele surgery

71% unable to walk independently

62% clean intermittent catheterizations



Adjuvant strategies are needed to augment spinal cord repair and improve prognosis



Adzick, NEJM, 2011Adzick, Pediatrics 2020Farmer, AJOG, 2017Brock 3rd, J.Urol, 2019



Objective



To experiment a patch of mesenchymal stromal cells (MSC)

as an adjuvant treatment for fetal myelomeningocele (MMC) surgery

in the ovine model of MMC



### Umbilical Cord-Mesenchymal Stromal Cells (UC-MSC)





### **Cells** characterization







### Patch of UC-MSCs

17 million MSCs Fibrin patch Fibrinogen Thrombin solution solution Polymerization 10 min - 37°C 0 ۲ O .

#### Homogeneous distribution

Migration within the mesh





Polymerization

### In vivo experiments of ovine UC-MSCs patch

- Animal model: surgical ovine model of MMC
- Comparison of two groups:
  - UC-MSC patch + skin suture
  - Acellular patch + skin suture
- Surgical protocole:



### Clinical examination

#### Score: SHEEP LOCOMOTOR RATING

validated in the ovine model of MMC



	Grade 0: complete paraplegia, no movement of any joints
/ERE	Grade 1: total of 1-3 points for joint movement
	Grade 2: total of 4-6 points for joint movement
SE	Grade 3: total of 7-9 points for joint movement
	Grade 4: total of 10-12 points for joint movement
	Grade 5: capable of stance with help, ≥4 joints with slight movement
ATI	Grade 6: capable of stance with help, ≥4 joints with extensive movement
ER	Grade 7: capable of spontaneous hindlimb weight support, ≥4 joints with slight movement
8	Grade 8: capable of spontaneous hindlimb weight support, ≥4 joints with extensive movement
Σ	Grade 9: capable of stance with help, capable of 1-4 steps
	Grade 10: capable of stance with help, capable of ≥5 steps with no or occasional forelimb-hindlimb coordination
	Grade 11: capable of stance with help, capable of ≥5 steps with frequent forelimb-hindlimb coordination
•	Grade 12: capable of standing up spontaneously on hindlimbs, capable of 0-4 steps
MIL	Grade 13: capable of standing up spontaneously on hindlimbs, capable of ≥5 steps with no or occasional forelimb-hindlimb coordination
	Grade 14: capable of standing up spontaneously on hindlimbs, capable of ≥5 steps with frequent forelimb-hindlimb coordination, not able to pass hindlimb clearance test
NORMAL	Grade 15: capable of standing up spontaneously on hindlimbs, capable of ≥5 steps with frequent forelimb-hindlimb coordination, able to pass hindlimb clearance test



### Clinical examination (ovine UC-MSCs)

	UC-MSCs patch n = 5	acellular patch n = 4	Р
SLR at 2 hours of life	2 [1-7]	2 [1-6]	0.8
SLR at 24 hours of life	14 [13-15]	5 [4-14]	0.04
Hind limbs amyotrophy	0 (0%)	3 (75%)	0.02
Incontinence	0 (0%)	4 (100%)	0.002







### Histological examination (ovine UC-MSCs)

	UC-MSC patch n = 5	Acellular patch n = 4	Р
Fibrosis thickness between spinal cord and dermis (µm)	453 (139 -872)	3921 (1469-52401)	0.03
Fibrosis thickness around spinal cord ( $\mu m$ )	48 (0 – 58)	158 (137 – 176)	<b>10</b> -4
Grey matter area (mm2)	8.2 (0.5 – 12.5)	7.1 (0.3 – 8.9)	NS
Spinal cord area (mm2)	21.8 (14.8 – 24.5 )	16.7 (13.5 – 21.0)	NS
<b>Neuronal density</b> (number of large neurons/mm <sup>2</sup> )	14.5 (10.8-17.7)	5.6 (5.2 - 8.9)	10 <sup>-3</sup>
Tumor	0	0	NS



Guilbaud 2021



Athiel 2023



### UC-MSCs potential side effects





# UC-MSCs potential side effects

#### Follow-up of *h*UC-MSCs lambs



#### **Safety of Cell Therapy with Mesenchymal Stromal Cells** (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials

Manoj M. Lalu<sup>1,5</sup>, Lauralyn McIntyre<sup>2,5</sup>\*, Christina Pugliese<sup>5</sup>, Dean Fergusson<sup>5</sup>, Brent W. Winston<sup>6</sup>, John C. Marshall<sup>7</sup>, John Granton<sup>8</sup>, Duncan J. Stewart<sup>3,4</sup>, for the Canadian Critical Care Trials Group

# The safety of MSC therapy over the past 15 years: a meta-analysis

Yang Wang<sup>1\*†</sup>, Hanxiao Yi<sup>2†</sup> and Yancheng Song<sup>1\*</sup>

Placental Mesenchymal Stromal Cells: Preclinical Safety Evaluation for Fetal Myelomeningocele Repair

Jordan E Jackson, MD,<sup>a,b,\*</sup> Christopher Pivetti, MS,<sup>b</sup> Sarah C Stokes, MD,<sup>a,b</sup> Christina M Theodorou, MD,<sup>a,b</sup> Priyadarsini Kumar, PhD,<sup>b</sup> Zachary J Paxton, BS,<sup>b</sup> Alicia Hyllen, BS,<sup>b</sup> Lizette Reynaga, BS,<sup>b</sup> Aijun Wang, PhD,<sup>b</sup> and Diana L Farmer, MD<sup>a,b</sup> 2012

2021

# Conclusion : UC-MSCs in fetal MMC surgery

#### Efficiency

# Clinical benefits motor function urinary function ? Preservation of large neurons Prevention from fibrosis

#### No risk

Transplantation of allogenic UC-MSCs does not seem to be associated with any side effect

#### Perspectives

- Better understand the mechanisms of action
- Clinical trial



# Satisfaction survey " your feed back"

https://forms.office.com/e/KCcLh2rb71

















Webinar T&E ERN ITHACA